This study sought to test the association between ecstasy-use and abnormal sleep. An anonymous web-based questionnaire containing questions on drug use and sleep was completed by 1035 individuals. From this large sample, a group of 89 ecstasy users were found who reported very little use of other drugs. This ”ecstasy-only“ group was further divided into two groups of 31 current users and 58 abstinent users. The subjective sleep of current and former ecstasy-only users was compared with that of matched controls. Patients were asked to rate their sleep according to: 1) sleep quality, 2) sleep latency, 3) night time awakenings and 4) total sleep time. Current ecstasy-only users reported significantly worse sleep quality (P < 0.05) and a greater total sleep time (P < 0.001) than controls. It was inferred that these differences might be due to recovery from the acute effects of the drug. Abstinent ecstasy-only users reported significantly more nighttime awakenings than controls (P < 0.01). These subjective findings are in agreement with the objective findings of previous studies showing persistent sleep abnormalities in ecstasy users.
Allen RP McCann UD Ricaurte GA (1993) Persistent effects of (±)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) on human sleep.Sleep16: 560–564.
2.
Barratt ES Beaver W White R (1974) The effects of marijuana on human sleep patterns.Biol Psychiatry8: 47–54.
3.
Battaglia G Yeh SY O'Hearn E Molliver ME Kuhar MJ de Souza EB (1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.J Pharmacol Exp Ther242: 911–916.
4.
Biello SM Dafters RI (2001) MDMA and fenfluramine alter the response of the circadian clock to a serotonin agonist in vitro.Brain Res920: 202–209.
5.
Buchert R Thomasius R Wilke F Petersen K Nebeling B (2004) A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters.Am J Psychiatry161: 1181–1189.
6.
Colbron S Jones M Biello SM (2002) MDMA alters the response of the circadian clock to a photic and non-photic stimulus.Brain Res956: 45–52.
7.
Comer SD Hart CL Ward AS Haney M Foltin RW Fischman MW (2001) Effects of repeated oral methamphetamine administration in humans.Psychopharmacology (Berl)155: 397–404.
8.
Curran HV Rees H Hoare T Hoshi R Bond A (2004) Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users.Psychopharmacology (Berl)173: 425–433.
9.
De Win MM Reneman L Reitsma JB den Heeten GJ Booij J . van den, BW (2004). Mood disorders and serotonin transporter density in ecstasy users – the influence of long-term abstention, dose, and gender.Psychopharmacology (Berl)173: 376–382.
10.
Fischer C Hatzidimitriou G Wlos J Katz J Ricaurte G (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”).J Neurosci15: 5476–5485.
11.
Gardani M Blance RN Biello SM (2005) MDMA alters the response of the mammalian circadian clock in hamsters: effects on re-entrainment and triazolam-induced phase shifts.Brain Res1046: 105–115.
12.
Guillot C Greenway D (2006) Recreational ecstasy use and depression.J Psychopharmacol20: 411–416.
13.
Hatzidimitriou G McCann UD Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery.J Neurosci19: 5096–5107.
14.
Iversen L (2006) Speed, Ecstasy, Ritalin. The Science of Amphetamines. Oxford University Press, Oxford.
15.
Johanson CE Roehrs T Schuh K Warbasse L (1999) The effects of cocaine on mood and sleep in cocaine-dependent males.Exp Clin Psychopharmacol7: 338–346.
16.
Jouvet M (1999) Sleep and serotonin: an unfinished story.Neuropsychopharmacology21(Suppl. 2): 24S-27S.
17.
Kirilly E Molnar E Balogh B Kantor S Hansson SR Palkovits M Bagdy G (2008) Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days.International Journal of Neuropsychopharmacology8: 1–15.
18.
McCann UD Eligulashvili V Ricaurte GA (2000) (±)3,4-Methylenedioxymethamphetamine (“Ecstasy”)-induced serotonin neurotoxicity: clinical studies.Neuropsychobiology42: 11–16.
19.
McCann UD Peterson SC Ricaurte GA (2007) The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users.Neuropsychopharmacology 32(8): 1695–1706.
20.
McCann UD Ricaurte GA Molliver ME (2001) “Ecstasy” and serotonin neurotoxicity: new findings raise more questions.Arch Gen Psychiatry58: 907–908.
21.
McCann UD Szabo Z Scheffel U Dannals RF Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings.Lancet352: 1433–1437.
22.
McCann UD Szabo Z Seckin E Rosenblatt P Mathews WB (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.Neuropsychopharmacology30: 1741–1750.
23.
Mechan A Yuan J Hatzidimitriou G Irvine RJ McCann UD Ricaurte GA (2006) Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons.Neuropsychopharmacology31: 339–350.
24.
Meyer JS Brevard ME Piper BJ Ali SF Ferris CF (2006) Neural effects of MDMA as determined by functional magnetic resonance imaging and magnetic resonance spectroscopy in awake marmoset monkeys.Ann N Y Acad Sci1074: 365–376.
25.
Montgomery C Fisk JE Newcombe R Murphy PN (2005) The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory.Psychopharmacology (Berl)182: 262–276.
26.
Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects.Psychopharmacology (Berl)152: 230–248.
27.
Morgan MJ McFie L Fleetwood H Robinson JA (2002) Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?Psychopharmacology (Berl)159: 294–303.
28.
Morgan PT Pace-Schott EF Sahul ZH Coric V Stickgold R Malison RT (2006) Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: evidence for occult insomnia.Drug Alcohol Depend82: 238–249.
29.
Morin CM Rodrigue S Ivers H (2003) Role of stress, arousal, and coping skills in primary insomnia.Psychosom Med65: 259–267.
30.
Parrott AC (2006) MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.J Psychopharmacol20: 147–163.
31.
Parrott AC Milani RM Gouzoulis-Mayfrank E Daumann J (2007). Cannabis and ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users.J Neural Transm114: 959–968.
32.
Reneman L Booij J Majoie CB . van den, BW, den Heeten, GJ (2001) Investigating the potential neurotoxicity of ecstasy (MDMA): an imaging approach.Hum Psychopharmacol16: 579–588.
33.
Ricaurte GA Martello AL Katz JL Martello MB (1992) Lasting effects of (±)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations.J Pharmacol Exp Ther261: 616–622.
34.
Saadat KS Elliott JM Colado MI Green AR (2004) Hyperthermic and neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) in guinea pigs.Psychopharmacology (Berl)173: 452–453.
35.
Sabol KE Seiden LS (1998) Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis.Brain Res806: 69–78.
36.
Scheffel U Ricaurte GA (1990) Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neurotoxicity: a presynaptic serotonergic positron emission tomography ligand?Brain Res527: 89–95.
37.
Semple DM Ebmeier KP Glabus MF O'Carroll RE Johnstone EC (1999). Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users.Br J Psychiatry175: 63–69.
38.
Soar K Parrott AC Fox HC (2004) Persistent neuropsychological problems after 7 years of abstinence from recreational ecstasy (MDMA): a case study.Psychol Rep95: 192–196.
39.
Thomasius R Gouzoulis-Mayfrank E Karus C Wiedenmann H Hermle L (2004) AWMF-guideline: cocaine-, amphetamine-, ecstasy- and hallucinogen-related disorders.Fortschr Neurol Psychiatr72: 679–695.
40.
Topp L Hando J Dillon P Roche A Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm.Drug Alcohol Depend55: 105–115.
41.
Ursin R (2002) Serotonin and sleep.Sleep Med Rev6: 55–69.
42.
Vollenweider FX Gamma A Liechti M Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers.Neuropsychopharmacology19: 241–251.
43.
Von Geusau NA Stalenhoef P Huizinga M Snel J Ridderinkhof KR (2004) Impaired executive function in male MDMA (“ecstasy”) users.Psychopharmacology (Berl)175: 331–341.
